Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;12(1):159-69.
doi: 10.1080/21645515.2015.1071455. Epub 2015 Sep 17.

Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review

Eva van Doorn  1 , Heng Liu  1 , Anke Huckriede  2 , Eelko Hak  1
Affiliations

Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review

Eva van Doorn et al. Hum Vaccin Immunother. 2016.

Abstract

Montanide ISA™51 (ISA 51) is a vaccine adjuvant which has been tested in therapeutic and prophylactic vaccine trials. The aim of this review is to present a comprehensive examination of the safety and tolerability of ISA 51 containing vaccines. A systematic literature search was conducted in PubMed, EMBASE and clinicaltrials.gov . Eligible studies were categorized into: (A) uncontrolled studies with non-healthy subjects, (B) controlled studies with non-healthy subjects, and (C) controlled studies with healthy subjects. Reported adverse events (AEs) were assessed. 91 studies were included in our review. Generally observed AEs included injection site reaction; injection site pain; myalgia; headache; gastro-intestinal disorders; fatigue and fever - regardless of the administration route and subject characteristic. Specific AEs, e.g. injection site reactions and rash, were more frequently reported from subjects receiving ISA 51-adjuvanted vaccines than from subjects receiving antigen or ISA 51 only. The reported AEs were mainly mild to moderate in intensity. Serious AEs (SAEs) were reported in 27% of the uncontrolled trials and 2 trials conducted with healthy subjects. Notably, 2 other trials conducted with healthy subjects were stopped due to unacceptable AEs. Some studies indicate that the mixing procedure of antigen and adjuvant might influence the occurrence of AEs. Reports on SAEs and premature termination of 2 trials advise caution when using ISA 51. Yet, AEs might be preventable by proper mixing of vaccine and adjuvant to a stable emulsion. Trials including an active control group are needed for a fair evaluation of adjuvant safety.

Keywords: ISA 51; Montanide; adverse event; safety; systematic review; tolerability.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart outlining study selection process for the ISA 51-adjuvanted vaccines studies included in the review.
See this image and copyright information in PMC

References

    1. WHO Annex 1 - guidelines for the production and quality control of synthetic peptide vaccines. WHO Technical Report Studies 1999; 889:24-43
    1. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: Current challenges and future approaches. J Pharm Sci 2009; 98:1278-316; PMID:18704954; http://dx.doi.org/10.1002/jps.21523 - DOI - PMC - PubMed
    1. European Medicines Agency Committee for medicinal products for human use guideline on adjuvants in vaccines for human use. 2004; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...
    1. Cox JV, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccine 1997; 15:248-56; PMID:9139482; http://dx.doi.org/10.1016/S0264-410X(96)00183-1 - DOI - PubMed
    1. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1:111-8; PMID:12908518; http://dx.doi.org/10.1586/14760584.1.1.111 - DOI - PubMed

Publication types

MeSH terms